- Home
- NETD vs TNGX Comparison
NETD vs TNGX Comparison
Compare NETD & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NETD
- TNGX
- Stock Information
- Founded
- NETD 2023
- TNGX 2014
- Country
- NETD United States
- TNGX United States
- Employees
- NETD N/A
- TNGX N/A
- Industry
- NETD
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- NETD
- TNGX Health Care
- Exchange
- NETD Nasdaq
- TNGX Nasdaq
- Market Cap
- NETD 422.4M
- TNGX 351.2M
- IPO Year
- NETD 2023
- TNGX N/A
- Fundamental
- Price
- NETD $11.17
- TNGX $6.82
- Analyst Decision
- NETD
- TNGX Strong Buy
- Analyst Count
- NETD 0
- TNGX 5
- Target Price
- NETD N/A
- TNGX $10.50
- AVG Volume (30 Days)
- NETD 243.1K
- TNGX 2.0M
- Earning Date
- NETD 01-01-0001
- TNGX 08-05-2025
- Dividend Yield
- NETD N/A
- TNGX N/A
- EPS Growth
- NETD N/A
- TNGX N/A
- EPS
- NETD 0.34
- TNGX N/A
- Revenue
- NETD N/A
- TNGX $40,990,000.00
- Revenue This Year
- NETD N/A
- TNGX N/A
- Revenue Next Year
- NETD N/A
- TNGX N/A
- P/E Ratio
- NETD $32.80
- TNGX N/A
- Revenue Growth
- NETD N/A
- TNGX 10.09
- 52 Week Low
- NETD $10.58
- TNGX $1.03
- 52 Week High
- NETD $11.47
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- NETD 54.61
- TNGX 71.71
- Support Level
- NETD $10.96
- TNGX $6.36
- Resistance Level
- NETD $11.24
- TNGX $7.20
- Average True Range (ATR)
- NETD 0.12
- TNGX 0.47
- MACD
- NETD 0.00
- TNGX -0.03
- Stochastic Oscillator
- NETD 41.18
- TNGX 77.91
About NETD Nabors Energy Transition Corp. II
Nabors Energy Transition Corp II is a blank check company.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.